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Summary
Background.  —  The  implementation  of  international  guidelines  for  antithrombotic  use  in  atrial
ﬁbrillation  (AF)  in  routine  practice  is  not  well  known,  particularly,  in  some  parts  of  the  world,
such as  the  Middle  East  and  Africa.
Aim.  —  To  describe  and  analyse  the  use  of  antithrombotics  in  patients  with  AF  in  routine
practice.
Methods.  —  The  RealiseAF  international  cross-sectional  survey  enrolled  10,523  patients  (with
at least  one  documented  AF  episode  in  the  preceding  12  months)  from  831  sites.  Participating
physicians  were  randomly  selected  from  physician  list  forms.
Results.  —  Mean  age  was  66.6  ±  12.2  years.  In  47.4%  of  the  patients  with  a  CHADS2 score  ≥  2,
oral anticoagulants  were  not  prescribed.  Patients  who  had  a  CHADS2 score  ≥  2,  permanent  or
persistent  AF,  valvular  heart  disease,  a  stroke  leading  to  hospitalization  in  the  previous  year  or
treatment by  a  cardiologist  (rather  than  an  internist)  were  most  likely  to  receive  oral  anticoagu-
lants. Patients  aged  ≥  75  years  and  those  with  coronary  heart  disease;  major  bleeding  leading  to
hospitalization  in  the  previous  year  or  a  rhythm  control  strategy  was  least  likely  to  receive  oral
anticoagulants.  Appropriate  antithrombotic  treatment  was  prescribed  in  66.7%  of  the  patients
with a  CHADS2 score  ≥  2  in  the  Middle  East/Africa,  55.3%  in  Europe,  43.9%  in  Latin  America  and
31.7% in  Asia.
Conclusion.  —  There  is  substantial  deviation  from  international  guidelines  in  antithrombotic  use
for AF  in  routine  clinical  practice,  with  overuse  and  underuse  of  antithrombotics  in  about  50%
of the  cases  and  important  geographical  differences.  These  ﬁndings  emphasize  the  need  for
improved medical  education  worldwide  and  a  better  understanding  of  geographical  disparities
in the  implementation  of  guidelines.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’impact  des  recommandations  internationales  dans  la  pratique  courante  concer-
nant l’utilisation  d’antithrombotiques  dans  la  ﬁbrillation  atriale  (FA)  n’est  pas  bien  connu
particulièrement  dans  certaines  parties  du  monde  comme  le  Moyen  Orient  et  l’Afrique.
Objectif.  —  Décrire  et  analyser  l’utilisation  d’antithrombotiques  chez  les  patients  souffrant  de
FA dans  la  pratique  courante.
Méthodologie.  — L’enquête  croisée  internationale  RealiseAF  incluait  10  523  patients
(avec ≥  1  épisode  de  FA  documenté  au  cours  des  12  mois  précédents)  dans  831  centres.
Les médecins  participants  ont  été  sélectionnés  par  tirage  au  sort  à  partir  de  listes  de  médecins.
Résultats.  — La  moyenne  d’âge  était  de  66,6  ±  12,2  ans.  Chez  47,4  %  des  patients  présentant
un score  CHADS2 ≥  2,  aucun  anticoagulant  oral  (ACO)  n’a  été  prescrit.  Les  patients  présentant
des scores  CHADS2 ≥  2,  avec  une  FA  permanente  ou  persistante  et  une  cardiopathie  valvulaire,
qui avaient  présenté  un  AVC  nécessitant  une  hospitalisation  au  cours  de  l’année  précédente
et qui  avaient  été  traités  par  un  cardiologue  (plutôt  qu’un  interniste),  étaient  plus  enclins
à recevoir  des  ACO.  Les  patients  âgés  de  75  ans  et  plus,  souffrant  d’une  coronaropathie  et
ayant développé  un  saignement  majeur  nécessitant  une  hospitalisation  au  cours  de  l’année
précédente,  et  les  patients  faisant  l’objet  d’une  stratégie  de  contrôle  du  rythme,  étaient  moins
enclins à  recevoir  des  ACO.  Un  traitement  antithrombotique  adapté  a  été  prescrit  chez  66,7  %
des patients  présentant  un  score  CHADS2 ≥  2  au  Moyen  Orient/en  Afrique,  55,3  %  des  patients
en Europe,  43,9  %  des  patients  en  Amérique  latine  et  31,7  %  des  patients  en  Asie.
Conclusion.  —  On  observe  une  déviation  considérable  par  rapport  aux  recommandations  inter-
nationales  concernant  l’utilisation  d’antithrombotiques  pour  la  FA  dans  la  pratique  clinique,
avec une  sur-utilisation  et  une  sous-utilisation  des  antithrombotiques  dans  environ  50  %  des  cas,
et avec  d’importantes  différences  géographiques.  Ces  résultats  soulignent  la  nécessité  d’une
meilleure  éducation  médicale  et  d’une  meilleure  compréhension  des  disparités  géographiques
dans la  mise  en  application  des  recommandations.
.  Tou
B
A
a
A© 2014  Elsevier  Masson  SAS
ackgroundtrial  ﬁbrillation  (AF)  is  the  most  common  sustained  cardiac
rrhythmia,  affecting  1—2%  of  the  general  population  [1,2].
s
a
ls  droits  réservés.
 crucial  aspect  of  AF  management  is  the  prevention  of
troke,  using  antithrombotic  therapy  (anti-platelets  and  oral
nticoagulants  [OACs])  [1—4].  Although  international  guide-
ines  provide  simple  rules  for  the  use  of  antithrombotics  in
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patients  with  AF,  the  implementation  of  these  guidelines
in  routine  practice  around  the  globe,  particularly  outside
Europe  and  North  America,  is  not  well  known  [3,5—8].
The  real-life  global  survey  evaluating  patients  with  AF
(RealiseAF)  survey  was  established  to  investigate  patient
characteristics,  cardiovascular  risk,  types  of  AF,  symptoms
and  medical  history  and  management  practices,  including
the  use  of  antithrombotics  [9],  in  routine  clinical  practice,
across  a  broad  range  of  geographic  settings  worldwide.  The
present  analysis  aimed  to  describe  the  use  and  determinants
of  use  of  antithrombotic  agents  in  patients  with  AF  in  the
regions  participating  in  the  RealiseAF  survey.
Methods
Design
As  previously  reported,  RealiseAF  was  a  cross-sectional
observational  survey  that  enrolled  10,546  patients  with  AF
at  831  sites  in  26  countries,  from  October  2009  to  May  2010
[9].
Patients
To  be  eligible  for  enrolment,  patients  had  to  have  a  history
of  AF  (treated  or  untreated),  with  at  least  one  AF  episode
documented  by  standard  electrocardiogram  or  Holter  elec-
trocardiogram  in  the  last  12  months,  or  documented  current
AF.  Exclusion  criteria  included  mental  disability,  inability
to  provide  written  informed  consent,  AF  occurring  within
3  months  of  cardiac  surgery,  and  participation  in  clinical  tri-
als  in  the  AF  or  antithrombotic  ﬁeld  in  the  previous  month.
All  patients  provided  written  informed  consent.  Participat-
ing  physicians  were  randomly  selected  from  physician  list
forms  [9].  Twenty-six  countries  from  four  continents  partic-
ipated  in  the  survey  (Appendix  A).
Objectives
The  main  objectives  of  the  present  analysis  were  to  describe
the  use  of  antithrombotic  agents  among  the  RealiseAF
patients  as  a  function  of  the  CHADS2 score  (Congestive
heart  failure,  Hypertension,  Age  >  75  years,  Diabetes  melli-
tus  and  Stroke  or  transient  ischaemic  attack  [2  points]);  to
assess  compliance  with  the  2006  American  College  of  Car-
diology  (ACC)/American  Heart  Association  (AHA)/European
Society  of  Cardiology  (ESC)  guidelines  (which  are  relevant
to  patients  enrolled  between  2009  and  2010)  [3];  and  to
analyse  the  results  according  to  geographic  region  and  type
of  AF  (paroxysmal,  persistent  or  permanent).  In  this  analy-
sis,  the  CHADS2 score  was  also  calculated  in  patients  with
valvular  disease.
Statistical analyses
Details  of  how  the  sample  size  was  determined  have  been
described  previously  [9].  Population  characteristics  were
summarized  by  means  ±  standard  deviations  for  continu-
ous  variables  and  by  counts  (percentages)  for  qualitative
variables.  Comparisons  between  subgroups  were  made  using
the  chi2 test  or  analysis  of  variance  as  appropriate.  To
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dentify  factors  associated  with  use  of  OACs  in  AF  patients
ith  a  CHADS2 score  ≥  2,  a multivariable  stepwise  logistic
egression  was  performed,  using  a  P  value  of  0.05  to  retain
he  variable  in  the  model.  Variables  tested  were:  age  by
lass;  obesity;  hypertension;  left  ventricular  hypertrophy;
istory  of  heart  failure  by  New  York  Heart  Association  class;
istory  of  coronary  artery  disease;  history  of  cerebrovascu-
ar  disease;  history  of  valvular  heart  disease;  type  of  AF;
ime  since  AF  diagnosis  by  class;  AF  management  strategy
hosen  before  the  enrolment  visit;  major  bleeding  lead-
ng  to  hospitalization  in  the  last  12  months;  stroke  leading
o  hospitalization  in  the  last  12  months;  and  speciality  of
hysician  and  practice  (public/private).  Discrimination  was
ssessed  using  c-statistics  and  calibration  was  assessed  using
osmer—Lemeshow  statistics.  The  odds  ratios  and  associ-
ted  95%  conﬁdence  intervals  for  the  use  of  OACs  were
etermined.  Multivariable  analysis  was  adjusted  for  country.
nalyses  were  performed  using  SAS® statistical  software,
ersion  9.2  (SAS  Institute,  Cary,  NC,  USA).
esults
articipating physicians
 total  of  831  physicians  participated  in  the  survey.
mong  these,  information  regarding  speciality  was  avail-
ble  for  803.  The  majority  were  cardiologists  (667/803;
3.1%),  while  around  1  in  10  were  internists  (63/803;  7.8%)
r  reported  both  specialities  (cardiologist  and  internist,
3/803;  9.1%).
atient characteristics
f  the  10,546  patients  enrolled,  10,523  constituted  the  ana-
ysed  population.  Twenty-three  patients  were  ineligible,  due
o  no  history  of  AF  (n  =  6),  mental  illness  (n  =  1),  post-cardiac
urgery  AF  (n  =  1),  clinical  trial  in  AF  or  antithrombotic  treat-
ent  in  the  previous  month  (n  =  3)  or  other  reasons  (n  =  14)
one  patient  had  three  reasons  for  ineligibility).  Patients  had
 mean  age  of  66.6  ±  12.2  years  and  56.4%  were  male.  AF  was
aroxysmal  in  24.8%,  persistent  in  22.3%  and  permanent  in
6.4%  of  patients;  the  remaining  6.4%  had  their  ﬁrst  episode
f  AF,  thereby,  preventing  assignation  to  one  of  the  previous
ategories.
Among  the  RealiseAF  population,  12.5%  of  the  patients
ad  a  CHADS2 score  of  0,  27.9%  had  a  score  of  1  and  59.6%
ad  a  score  of  ≥  2.  Consistent  with  the  elements  constituting
he  score,  the  population  of  patients  with  a  CHADS2 score  ≥  2
as  older,  had  a  higher  prevalence  of  cardiovascular  risk  fac-
ors,  particularly  diabetes  and  hypertension,  and  was  more
ikely  to  have  permanent  AF  and  heart  failure  (Table  1).
atient  characteristics  according  to  region  and  type  of  AF
re  presented  in  Tables  2  and  3.
se of OACs according to CHADS2 score
here  was  an  important  discrepancy  between  guideline  rec-
mmendations  [3]  and  actual  use  of  antithrombotics  as  a
unction  of  the  CHADS2 scores  (Fig.  1).  In  46.0%  of  the
atients  with  a  CHADS2 score  of  0,  OACs  were  prescribed.
his  varied  depending  on  the  type  of  AF,  with  23.5%,  52.8%
80  H.  Gamra  et  al.
Table  1  Patient  characteristics  according  to  the  CHADS2  score.
Characteristic  CHADS2 score  P
0
(n  =  1262)
1
(n  =  2810)
≥  2
(n  =  6004)
Age  (years) 55.3  ±  12.3 62.6  ±  10.8 70.7  ±  10.5 <  0.0001
Age  ≥  75  years  0  8.1  42.7  <  0.0001
Male  62.7  57.4  54.4  <  0.0001
Type  of  AF  <  0.0001
Paroxysmal  32.1  29.6  21.5
Persistent  24.2  23.8  21.3
Permanent  33.4  39.4  52.3
First  episode 10.2  7.1  5.0
Paroxysmal  +  persistent  <  0.1  0  0
Hypertension  0  64.5  90.2  <  0.0001
Diabetes  mellitus  0  4.1  33.5  <  0.0001
Obesity,  BMI  ≥  30  kg/m2 20.2  32.2  35.8  <  0.0001
Smoking  <  0.0001
Current  smoker 14.0  10.5  9.1
Never  or  former  smoker  86.0  89.5  90.9
Dyslipidaemia  21.5  36.9  55.6  <  0.0001
Heart  failure  in  class < 0.0001
No  HF  or  NYHA  class  I 100  80.4  43.1
NYHA  class  II 0 11.5  36.1
NYHA  class  III  or  IV 0  8.1  20.8
Coronary  artery  disease 8.3  18.4  43.4  <  0.0001
Valvular  heart  disease 23.3  25.4  27.5  0.0033
PCI  in  the  last  12  months 2.4  4.1  8.0  <  0.0001
AF  management  strategy  chosen  for  AF
before  this  visit
< 0.0001
Rhythm  control  41.9  40.9  30.6
Rate  control  39.1  47.6  59.7
Rhythm  control  +  rate  control  0  0.1  < 0.1
None  19.0  11.4  9.7
Data are mean ± standard deviation or %; AF: atrial ﬁbrillation; BMI: body mass index; CHADS2: Congestive heart failure, Hypertension,
Age > 75 years, Diabetes mellitus and Stroke or transient ischaemic attack (2 points); HF: heart failure; NYHA: New York Heart
Association; PCI: percutaneous coronary intervention.
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ynd  56.4%  of  the  patients  with  paroxysmal,  persistent  and
ermanent  AF,  respectively,  with  a  CHADS2 score  of  0,  pre-
cribed  OACs.  However,  OACs  were  not  prescribed  in  47.4%
f  the  patients  with  a  CHADS2 score  ≥  2  (Fig.  1).  While  guide-
ines  would  have  recommended  the  use  of  anti-platelet
gents  in  patients  with  a  CHADS2 score  of  0,  only  24.8%
f  the  patients  received  appropriate  anti-platelet  therapy.
urthermore,  a  consistent  ﬁnding  across  the  CHADS2 score
ategories  was  the  substantial  proportion  of  patients  not
eceiving  any  antithrombotic  treatment,  ranging  from  29.2%
n  patients  with  a  CHADS2 score  of  0,  to  25.7%  in  patients
ith  a  CHADS2 score  of  1  and  19.1%  in  patients  with  a  CHADS2
core  of  ≥  2.
eographical differencesn  this  analysis,  patients  with  AF  from  the  Middle  East
nd  Africa  were  signiﬁcantly  younger  and  more  frequently
emale  compared  with  those  originating  from  the  rest  of
he  world  (Table  2).  A  CHADS2 score  ≥  2  was  observed  in
H
a
t
(4.2%  of  the  patients  originating  from  Europe  versus  58.3%,
7.8%  and  43.6%  from  Latin  America,  Asia  and  the  Middle
ast  and  Africa,  respectively.  Among  those  patients  with
 CHADS2 score  ≥  2,  there  were  also  important  geographi-
al  differences  with  respect  to  the  use  of  antithrombotics:
he  proportion  of  patients  not  receiving  any  antithrombotic
herapy  ranged  from  11.4%  in  the  Middle  East  and  Africa
o  27.6%  in  Latin  America.  Conversely,  the  use  of  OACs  was
ighest  in  the  Middle  East  and  Africa  (66.7%)  and  lowest  in
sia  (31.7%)  (Fig.  2).
se of antithrombotics according to type of AF
he  prescription  rate  of  OACs  among  patients  with  a  CHADS2
core  ≥  2  was  higher  in  permanent  AF  (59.0%)  than  in  parox-
smal  and  persistent  AF  (37.7  and  54.4%,  respectively).
owever,  the  percentage  of  patients  not  receiving  any
ntithrombotic  therapy  in  that  population  was  similar  in
he  three  groups  (17.9%,  20.5%  and  19.8%,  respectively)
Fig.  3).
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Table  2  Patient  characteristics  according  to  region.
Characteristic  Region  P
Asia
(n  =  1703)
Europe
(n  =  6759)
Latin  America
(n  =  381)
Middle
East/Africa
(n  =  1680)
Age  (years) 66.4  ±  13.1 68.1  ±  10.8 66.0  ±  13.6 61.1  ±  14.2 < 0.0001
Age  ≥  75  years  31.1  29.6  30.4  17.9  <  0.0001
Male  54.1  59.6  57.0  45.8  <  0.0001
Type  of  AF  <  0.0001
Paroxysmal  26.1  26.5  23.8  17.2
Persistent  17.9  24.0  14.6  21.6
Permanent  48.2  44.3  57.1  50.5
First  episode  7.8  5.1  4.5  10.7
Paroxysmal  +  persistent  <  0.1  <  0.1  0  0
Hypertension  67.5  78.1  66.3  54.7  <  0.0001
Diabetes  mellitus  24.9  20.2  19.7  22.7  0.0001
Obesity,  BMI  ≥  30  kg/m2 18.7  35.9  36.5  33.0  <  0.0001
Smoking  <  0.0001
Current  smoker  10.0  9.6  5.2  13.7
Never  or  former  smoker 90.0  90.4  94.8  86.3
Dyslipidaemia  35.1  54.1  38.8  27.9  <  0.0001
Heart  failure  in  class < 0.0001
No  HF  or  NYHA  class  I 64.3  56.8  68.0  66.9
NYHA  class  II 21.8  27.9  25.2  16.5
NYHA  class  III  or  IV 13.9 15.3  6.8  16.6
Coronary  artery  disease 32.8  36.4  16.3  19.1  <  0.0001
Valvular  heart  disease 38.6  22.2  31.8  31.5  <  0.0001
PCI  in  the  last  12  months 6.4  6.1  3.9  7.2  0.0964
AF  management  strategy  chosen  for  AF
before  this  visit
< 0.0001
Rhythm  control  23.2  39.4  33.1  26.7
Rate  control  60.4  51.3  60.6  55.4
Rhythm  control  +  rate  control  <  0.1  <  0.1  0  0
None  16.3  9.2  6.3  17.9
Data are mean ± standard deviation or %; AF: atrial ﬁbrillation; BMI: body mass index; HF: heart failure; NYHA: New York Heart Association;
PCI: percutaneous coronary intervention.
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with CHADS2 score ≥ 2
In  AF  patients  with  a  CHADS2 score  ≥  2,  a  multivariable
logistic  regression  analysis  found  that  the  main  predictors
of  OAC  use  were:  age  <  75  years;  lack  of  coronary  artery
disease  and  major  bleeding  leading  to  hospitalization  in
the  last  12  months;  presence  of  persistent/permanent  AF
(as  opposed  to  paroxysmal);  history  of  valvular  disease;
presence  of  stroke  leading  to  hospitalization  in  the  last
12  months;  use  of  a  rate  control  strategy  or  rhythm  con-
trol  strategy  (as  opposed  to  no  strategy);  and  treatment  by
a  cardiologist  (as  opposed  to  an  internist,  Fig.  4).
DiscussionIn  this  large  international  survey,  we  found  that  in  rou-
tine  clinical  practice,  the  use  of  antithrombotics  in  patients
with  AF  deviates  from  current  guideline  recommendations
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oelating  to  CHADS2 scores,  with  both  overuse  and  underuse
f  OACs  reported.  This  ﬁnding  is  consistent  with  previ-
us  reports  in  Europe  and  North  America  [10—15].  OACs
ere  not  prescribed  in  54.0%  of  the  patients  with  a  CHADS2
core  of  0  and  47.4%  of  patients  with  a  CHADS2 score  ≥  2
Fig.  1).  This  is  particularly  noteworthy  considering  that
ACs  are  indicated  in  persistent  AF,  independent  of  the
HADS2 score.  While  guidelines  would  have  recommended
se  of  anti-platelet  agents  in  patients  with  a  CHADS2 score
f  0,  only  24.8%  of  the  patients  received  appropriate  anti-
latelet  therapy.  Even  so,  this  may  be  due  in  part  to  the  use
f  OACs  due  to  cardioversion,  which  may  lead  to  a  reduced
ercentage  of  patients  receiving  anti-platelets.  In  addition,
mportant  differences  were  observed  among  geographical
egions,  with  underuse  of  OACs  more  frequently  observed  in
he  Asian  population  compared  to  other  geographical  areas.
owever,  further  studies  are  required  to  determine  the  rea-
ons  for  these  differences.  One  such  study  is  the  ongoing
ARFIELD  AF  registry,  an  observational  prospective  study
f  patients  with  newly  diagnosed  AF  and  additional  risk
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Table  3  Patient  characteristics  according  to  type  of  atrial  ﬁbrillation.
Characteristic  Type  of  AF  P
Paroxysmal
(n  =  2606)
Persistent
(n  =  2341)
Permanent
(n  =  4869)
First  episode
(n  =  675)
Age  (years) 64.7  ±  12.4 66.0  ±  11.8 68.3  ±  11.8  64.2  ±  13.7  <  0.0001
Age  ≥  75  years 22.4  25.3  32.8  24.6  <  0.0001
Male  55.5  57.9  55.8  58.2  0.2235
Hypertension  74.6  73.2  71.6  64.2  <  0.0001
Diabetes  mellitus  19.1  19.3  23.5  21.6  <  0.0001
Obesity,  BMI  ≥  30  kg/m2 30.9  35.0  32.4  33.9  0.0214
Smoking  <  0.0001
Current  smoker  10.3  11.2  9.0  15.4
Never  or  former  smoker  89.7  88.8  91.0  84.6
Dyslipidaemia  50.4  48.2  44.4  37.2  <  0.0001
Heart  failure  in  class  <  0.0001
No  HF  or  NYHA  class  I  72.7  62.0  50.3  74.1
NYHA  class  II  20.0  24.3  29.5  14.6
NYHA  class  III  or  IV 7.3  13.7  20.2  11.3
Coronary  artery  disease  30.0  32.9  34.3  24.7  <  0.0001
Valvular  heart  disease 16.7  21.2  35.8  18.2  <  0.0001
PCI  in  the  last  12  months 7.3  6.6  5.7  5.1  0.0219
AF  management  strategy  chosen  for  AF  before  this  visit <  0.0001
Rhythm  control 67.8  51.9  9.0  28.6
Rate  control 18.8  37.0  84.2  27.9
Rhythm  control  +  rate  control <  0.1 0.2  0  0
None  13.3  10.8  6.8  43.6
: body mass index; HF: heart failure; NYHA: New York Heart Association;
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Figure 1. Use of antithrombotics in patients with atrial ﬁbril-
lation (AF) in a real-life setting according to the 2006 American
College of Cardiology/American Heart Association/European Soci-
ety of Cardiology guidelines: total population, showing the
distribution of antithrombotic treatment (anticoagulant, anti-
platelet, both or neither) in AF patients with a CHADS2 score of 0,Data are mean ± standard deviation or %; AF: atrial ﬁbrillation; BMI
PCI: percutaneous coronary intervention.
actors  for  stroke.  GARFIELD  AF  aims  to  enrol  55,000  patients
t  >  1000  centres  in  50  countries,  including  Argentina,  Aus-
ralia,  Brazil,  Canada  and  South  Africa  [16].  Currently,
7,000  patients  are  enrolled,  and  the  results  are  expected
o  add  to  our  understanding  of  treatment  patterns  for  stroke
revention  in  AF  across  more  diverse  geographical  regions.
The  implementation  of  treatment  guidelines  is  complex
nd  various  studies  have  shown  that  they  are  only  success-
ully  implemented  in  <  50%  of  the  cases  [14,17].  There  are
everal  reasons  that  may  explain  the  lack  of  adherence  to
reatment  guidelines  observed  in  this  analysis,  including:
ifﬁculties  in  extrapolating  clinical  trial  data  to  patients  who
ay  have  a  complex  medical  history;  lack  of  awareness;  lack
f  opportunity  to  evaluate  and  adapt  guidelines  to  local  clin-
cal  practice;  cultural  barriers;  psychological  factors  (e.g.
hysician  fear  of  bleeding/intracranial  haemorrhage);  and
conomic  issues  (which  are  particularly  apparent  in  devel-
ping  countries,  where  there  can  be  barriers  to  physicians
rescribing  effective  treatments  or  accessing  monitoring
ests  [18]).  The  lack  of  international  normalized  ratio  (INR)
onitoring  in  outpatient  clinics  in  some  countries  or  regions
nd  contraindications  to  OAC  use  in  some  patients  might
lso  explain  the  non-adherence  to  guidelines  [19].  Interest-
ngly,  the  rate  of  appropriate  use  of  antithrombotics  in  this
nalysis  was  highest  in  the  Middle  East  and  Africa,  which
ontain  some  of  the  poorest  regions  in  the  world  and  where
NR  monitoring  is  not  readily  available.
Risk  scores  in  stroke  and  treatment  guidelines  must  be
imple  and  consistent  to  avoid  confusion  among  clinicians
1 or ≥ 2. CHADS2: Congestive heart failure, Hypertension, Age > 75
years, Diabetes mellitus and Stroke or transient ischaemic attack (2
points).
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Figure 2. Use of antithrombotics in patients with atrial ﬁbrillation (AF) in a real-life setting according to the 2006 American College
of Cardiology/American Heart Association/European Society of Cardiology guidelines: geographical differences, showing the distribution
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and  non-uniform  use  of  anticoagulation  therapy  [18,20,21].
Variation  in  the  management  of  patients  with  AF  was  found
in  several  reports,  not  only  among  physicians  [22],  but
also  among  countries.  The  ADHERE-International  registry
reported  on  2358  patients  with  AF  from  10  Asia-Paciﬁc  and
Latin  American  countries;  it  reported  that  the  highest  and
lowest  rates  of  OAC  use  were  in  Australia  (65.2%)  and  Tai-
wan  (25.1%)  [23].  In  a  large  survey  from  Taiwan  including
39,541  patients  with  AF,  only  24.7%  of  the  overall  population
received  appropriate  antithrombotic  therapy  [24],  consis-
tent  with  the  ADHERE  ﬁndings.  Comparable  ﬁndings  were
reported  in  a  large  survey  conducted  in  the  USA  [17].  In
contrast,  in  the  French  EPHA  study  [25],  as  well  as  in  the  Ger-
man  AFNET  study  [26],  OACs  were  prescribed  in  a  very  high
proportion  of  patients  (68—93%).  Likewise,  recent  results
from  the  PREFER  registry  of  7243  patients  with  AF  from  Aus-
tria,  France,  Germany,  Italy,  Spain,  Switzerland  and  the  UK
showed  that  OACs  were  prescribed  in  82.3%  of  the  patients
[27].  Meanwhile,  results  from  Cohort  1  of  5  in  the  GARFIELD
AF  registry  (10,614  patients:  27.7%  from  Asia-Paciﬁc;  2.2%
1
t
l or ≥ 2, in the Middle East/Africa, Europe, Asia or Latin America.
s mellitus and Stroke or transient ischaemic attack (2 points).
rom  Canada;  8.1%  from  Central  and  South  America;  and
2.0%  from  Europe)  reported  antithrombotic  prescription  at
iagnosis  of  AF  in  60.3%  of  the  patients  [28].
In  the  present  analysis,  inappropriate  treatment  in
atients  with  a  CHADS2 score  ≥  2  was  observed  more  fre-
uently  in  Asia  and  Latin  America  compared  with  that  in
urope  and  the  Middle  East  and  Africa  (68.3%,  56.4%,  44.7%
nd  33.3%,  respectively).  The  reason  for  such  differences
s  not  clear,  but  there  are  probably  different  values  and
references  according  to  region  or  country  regarding  the
alance  of  risk  and  beneﬁt  of  antithrombotic  therapy.  The
erception  of  and  reported  higher  propensity  for  bleed-
ng  among  Asian  patients  [29]  may  explain  the  reluctance
f  some  physicians  to  prescribe  OACs  in  Asia  compared
o  those  in  other  regions  of  the  world  [29].  It  is  very
ikely  for  that  reason  that  the  Japanese  guidelines  on  the
anagement  of  AF  recommend  a  lower  INR  control  of
.6—2.6  in  patients  aged  ≥  70  years  [30],  compared  with
hat  recommended  by  the  European  and  American  guide-
ines.
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Figure 3. Use of antithrombotics in patients with atrial ﬁbrillation (AF) in a real-life setting according to the 2006 American College of
Cardiology/American Heart Association/European Society of Cardiology guidelines: types of AF, showing the distribution of antithrombotic
t ing to
t sion, 
a
p
w
l
d
(
c
n
l
l
T
r
ﬁ
b
a
b
T
w
s
a
s
s
t
w
a
p
t
I
r
b
o
l
o
A
sreatment in AF patients with a CHADS2 score of 0, 1 or ≥ 2, accord
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ttack (2 points).
In  terms  of  predicting  factors  for  prescribing  OACs  in
atients  with  a  CHADS2 score  ≥  2,  we  found  that  patients
ho  had  a  previous  stroke  leading  to  hospitalization  in  the
ast  12  months,  permanent  or  persistent  AF,  valvular  heart
isease  or  who  had  received  treatment  by  a  cardiologist
versus  an  internist)  were  most  likely  to  receive  OACs.  In
ontrast,  older  patients  aged  ≥  75  years,  patients  with  coro-
ary  artery  disease  and  patients  with  major  bleeding  events
eading  to  hospitalization  in  the  last  12  months  were  least
ikely  to  receive  OACs,  despite  having  a  CHADS2 score  ≥  2.
he  ﬁnding  that  older  patients  with  AF  are  less  likely  to
eceive  OACs  has  been  reported  previously  [31—33]. The
nding  that  patients  with  AF  and  a  CHADS2 score  ≥  2  who  had
een  cared  for  by  a  cardiologist  were  more  likely  to  receive
ppropriate  antithrombotic  treatment  than  those  cared  for
y  an  internist  has  also  been  observed  in  previous  studies.
hese  include  a  2006  study  to  evaluate  the  determinants  of
arfarin  use  in  patients  with  AF  in  the  USA  [34],  and  a  2001
tudy  conducted  to  assess  the  use  of  anticoagulation  ther-
py  in  patients  with  chronic  AF  in  Taiwan  [35].  However,  it
6
p
a
m whether the AF was paroxysmal, persistent, permanent or unable
Age > 75 years, Diabetes mellitus and Stroke or transient ischaemic
hould  be  noted  that  cardiologist  care  was  not  identiﬁed  as  a
igniﬁcant  factor  in  a  more  recent  USA  meta-analysis  aiming
o  determine  the  predictors  of  warfarin  use  among  patients
ith  AF  [36].
In  this  population,  a  number  of  patients  had  coronary
rtery  disease  with  an  indication  for  aspirin  and/or  clo-
idogrel.  The  condition  might  have  led  physicians  to  avoid
he  prescription  of  OACs,  fearing  bleeding  complications.
n  fact,  withholding  OACs  in  those  patients  carries  a  high
isk  of  thromboembolic  complications.  Hence,  there  must
e  a  compromise  between  the  risk  of  bleeding  and  the  risk
f  thromboembolism.  In  the  most  recent  2010  ESC  guide-
ines  [6], a  new  score  that  includes  a  vascular  component
f  CHADS2 score  (Congestive  heart  failure,  Hypertension,
ge  >  75  years  [2  points],  Diabetes  mellitus,  Stroke  or  tran-
ient  ischaemic  attack  [2  points],  Vascular  disease,  Age
5—74  years  and  sex  category  [female]  [CHA2DS2-VASC])  was
roposed  to  emphasize  the  importance  of  considering  the
ssociated  vascular  disease  in  patients  with  AF  for  the  deter-
ination  of  the  thromboembolic  risk  [37].  In  the  same
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Figure 4. Predictors of the use of oral anticoagulants in atrial ﬁbrillation (AF) patients with a CHADS2 score ≥ 2, showing the odds ratio
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Rof predictors of the use of oral anticoagulants in AF patients with a 
curve: 0.73. Hosmer—Lemeshow test: 0.26. Odds ratio adjusted by c
Diabetes mellitus and Stroke or transient ischaemic attack (2 point
guidelines,  a  score  for  the  risk  of  bleeding  (HAS-BLED;  Hyper-
tension,  Abnormal  renal/liver  function,  Stroke,  Bleeding
history  or  predisposition,  Labile  INR,  Elderly,  Drugs/alcohol
concomitantly)  was  also  proposed  [38,39].  The  combination
of  the  two  scores  allows  for  better  management  of  these
patients.
Limitations
This  analysis  has  some  limitations,  including  the  lack  of
longitudinal  follow-up,  due  to  its  cross-sectional  nature,
and  a  potential  for  recruitment  bias.  To  minimize  the
latter,  participating  physicians  were  identiﬁed  at  random
from  a  global  list  of  cardiologists  and  internists  (hospital-
and  ofﬁce-based).  Additionally,  the  2006  version  of  the
ACC/AHA/ESC  guidelines  [3]  was  used  as  the  evidence  base
for  proper  selection  of  antithrombotic  therapy  in  this  analy-
sis,  because  more  recent  ESC  [6]  and  American  [8]  guidelines
had  not  yet  been  released  when  the  study  was  conducted.
Therefore,  the  2006  guidelines  constituted  contemporary
evidence  when  physicians  selected  therapy.  The  2006  guide-
lines  also  recommended  the  use  of  the  CHADS2 score  for
quantifying  thromboembolic  risk,  but  this  has  since  been
superseded  by  the  CHA2DS2-VASc  score  [6].  Nevertheless,  as
the  main  focus  of  this  survey  was  patients  with  a  CHADS2
score  of  ≥  2  (due  to  their  higher  risk  of  thromboembolic
events),  reanalysis  of  the  data  using  the  CHA2DS2-VASc  score
would  have  added  limited  value  (i.e.  these  patients  would
still  have  been  at  higher  risk  for  such  events).  Thus,  conclu-
sions  regarding  antithrombotic  use  would  likely  have  been
similar.
Furthermore,  and  despite  the  wide  geographical  scope
of  this  analysis,  it  does  not  include  large  regions,  such
as  the  USA  or  Central  Africa.  However,  RealiseAF  does
have  unprecedented  geographical  relevance  by  including
non-white  populations  and  many  low-  and  middle-income
countries  in  the  developing  world,  where  the  epidemiology
and  management  of  AF  are  less  well  studied  [6]. The  inclu-
sion  of  patients  with  valvular  heart  disease  in  this  analysis
o
w
w
aS2 score ≥ 2. The model is based on 5347 observations. Area under
ry. CHADS2: Congestive heart failure, Hypertension, Age > 75 years,
ay  also  have  interfered  with  the  rate  of  OAC  use  and  may
xplain,  in  part,  the  higher  rate  of  appropriate  antithrom-
otic  treatment  in  countries  in  the  Middle  East  and  Africa,
here  valvular  heart  disease  is  more  prevalent.  In  addition,
n  those  patients  with  a  low  CHADS2 score,  the  rate  of  OAC
se  may  have  been  inﬂuenced  by  the  inclusion  of  patients
ndergoing  cardioversion,  in  whom  OAC  use  is  recommended
ccording  to  the  2006  ACC/AHA/ESC  guidelines  [3].  This
ould  unduly  lead  to  the  conclusion  that  OACs  are  overused
n  these  patients,  but  such  results  should  be  interpreted  with
aution.
onclusions
n  conclusion,  in  this  large  international  observational  sur-
ey,  the  management  of  AF  deviates  from  guidelines,  with
oth  overuse  and  underuse  of  antithrombotic  treatment  in
pproximately  50%  of  the  patients,  and  has  important  geo-
raphical  differences.  These  ﬁndings  emphasize  the  need
or  improved  medical  education  worldwide  and  for  a  better
nderstanding  of  geographical  disparities  in  the  implemen-
ation  of  guidelines.
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ppendix A.
wenty-six  countries  from  four  continents  participated  in
he  study:  Europe  (Belgium  [n  =  306],  Bulgaria  [n  =  450],
zech  Republic  [n  =  280],  Germany  [n  =  1074],  Hungary
n  =  506],  Ireland  [n  =  229],  Italy  [n  =  255],  Lithuania
n  =  452],  Portugal  [n  =  165],  Russia  [n  =  750],  Slovakia
n  =  439],  Spain  [n  =  487],  Sweden  [n  =  264],  Switzer-
and  [n  =  402],  Ukraine  [n  =  700]);  Latin  America  (Mexico
n  =  168],  Venezuela  [n  =  213]);  Asia  (Azerbaijan  [n  =  150],
ndia  [n  =  301],  Taiwan  [n  =  742],  Turkey  [n  =  510]);  and  the
iddle  East  and  Africa  (Algeria  [n  =  310],  Egypt  [n  =  458],
ebanon  [n  =  191],  Morocco  [n  =  250],  Tunisia  [n  =  471]).  For
he  purpose  of  analysing  the  results  by  geographical  region,
he  Middle  East  and  Africa  were  considered  as  one  region.
eferences
[1] Go AS, Hylek EM, Phillips KA, et al. Prevalence of diag-
nosed atrial ﬁbrillation in adults: national implications for
rhythm management and stroke prevention: the AnTicoagula-
tion and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA
2001;285:2370—5.
[2] Stewart S, Hart CL, Hole DJ, et al. Population prevalence,
incidence, and predictors of atrial ﬁbrillation in the Ren-
frew/Paisley study. Heart 2001;86:516—21.
[3] Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
Guidelines for the Management of Patients with Atrial Fibrilla-
tion: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the
European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Revise the 2001 Guidelines for the
Management of Patients With Atrial Fibrillation): developed in
collaboration with the European Heart Rhythm Association and
the Heart Rhythm Society. Circulation 2006;114:e257—354.
[4] Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for
stroke prevention in atrial ﬁbrillation: how well do randomized
trials translate into clinical practice? JAMA 2003;290:2685—92.
[H.  Gamra  et  al.
[5] Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovas-
cular Society atrial ﬁbrillation guidelines 2010: prevention of
stroke and systemic thromboembolism in atrial ﬁbrillation and
ﬂutter. Can J Cardiol 2011;27:74—90.
[6] Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the manage-
ment of atrial ﬁbrillation: the Task Force for the Management of
Atrial Fibrillation of the European Society of Cardiology (ESC).
Eur Heart J 2010;31:2369—429.
[7] Singer DE, Albers GW, Dalen JE, et al. Antithrombotic ther-
apy in atrial ﬁbrillation: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008;133:546S—92S.
[8] Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS
focused update on the management of patients with atrial
ﬁbrillation (Updating the 2006 Guideline): a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol
2011;57:223—42.
[9] Steg PG, Alam S, Chiang CE, et al. Symptoms, functional status
and quality of life in patients with controlled and uncontrolled
atrial ﬁbrillation: data from the RealiseAF cross-sectional inter-
national registry. Heart 2012;98:195—201.
10] Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of
the process and quality of oral anticoagulation management
in real-life practice in patients with chronic non-valvular atrial
ﬁbrillation: the international study of anticoagulation manage-
ment (ISAM). J Thromb Thrombolysis 2007;23:83—91.
11] Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-
associated hemorrhage: the anticoagulation and risk factors in
atrial ﬁbrillation study. J Am Geriatr Soc 2006;54:1231—6.
12] Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among
ambulatory patients with nonvalvular atrial ﬁbrillation: the
anticoagulation and risk factors in atrial ﬁbrillation (ATRIA)
study. Ann Intern Med 1999;131:927—34.
13] Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial ﬁbrillation
management: a prospective survey in ESC member countries:
the Euro Heart Survey on Atrial Fibrillation. Eur Heart J
2005;26:2422—34.
14] Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treat-
ment in real-life atrial ﬁbrillation patients: a report from
the Euro Heart Survey on Atrial Fibrillation. Eur Heart J
2006;27:3018—26.
15] Nilsson GH, Bjorholt I. Occurrence and quality of anticoagulant
treatment of chronic atrial ﬁbrillation in primary health care
in Sweden: a retrospective study on electronic patient records.
BMC Clin Pharmacol 2004;4:1.
16] Kakkar AK, Mueller I, Bassand JP, et al. International longi-
tudinal registry of patients with atrial ﬁbrillation at risk of
stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).
Am Heart J 2012;163:13—90.
17] Zimetbaum PJ, Thosani A, Yu HT, et al. Are atrial ﬁbrillation
patients receiving warfarin in accordance with stroke risk? Am
J Med 2010;123:446—53.
18] Faergeman O. Challenges to best practice: why  are guidelines
not implemented? Eur Heart J 1999;1:J12—7.
19] Gattellari M, Worthington J, Zwar N, et al. Barriers to the
use of anticoagulation for nonvalvular atrial ﬁbrillation: a
representative survey of Australian family physicians. Stroke
2008;39:227—30.
20] Comparison of 12 risk stratiﬁcation schemes to predict
stroke in patients with nonvalvular atrial ﬁbrillation. Stroke
2008;39:1901—10.
21] Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anti-
coagulants in atrial ﬁbrillation: a systematic review. Am J Med
2010;123:638—450000.22] Lip GY, Zariﬁs J, Watson RD, et al. Physician variation in
the management of patients with atrial ﬁbrillation. Heart
1996;75:200—5.
[[
[
[
[
[
[Use  of  antithrombotics  in  atrial  ﬁbrillation  
[23] Suarez J, Piccini JP, Liang L, et al. International variation in
use of oral anticoagulation among heart failure patients with
atrial ﬁbrillation. Am Heart J 2012;163:804—11.
[24] Guidelines for good pharmacoepidemiology practices (GPP).
Pharmacoepidemiol Drug Saf 2008;17:200—8.
[25] Cohen A, Dallongeville J, Durand-Zaleski I, et al. Characteris-
tics and management of outpatients with history of or current
atrial ﬁbrillation: the observational French EPHA study. Arch
Cardiovasc Dis 2010;103:376—87.
[26] Nabauer M, Gerth A, Limbourg T, et al. The Registry of
the German Competence NETwork on Atrial Fibrillation:
patient characteristics and initial management. Europace
2009;11:423—34.
[27] Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial
ﬁbrillation in seven European countries after the publication of
the 2010 ESC Guidelines on atrial ﬁbrillation: primary results of
the PREvention oF thromboemolic events — European Registry
in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6—14.
[28] Kakkar AK, Mueller I, Bassand JP, et al. Risk proﬁles and
antithrombotic treatment of patients newly diagnosed with
atrial ﬁbrillation at risk of stroke: perspectives from the inter-
national, observational, prospective GARFIELD registry. PLoS
One 2013;8:e63479.
[29] Jiang B, Wang WZ, Chen H, et al. Incidence and trends of stroke
and its subtypes in China: results from three large cities. Stroke
2006;37:63—8.
[30] Guidelines for pharmacotherapy of atrial ﬁbrillation (JCS
2008): digest version. Circ J 2010;74:2479—500.
[31] Cohen N, Almoznino-Saraﬁan D, Alon I, et al. Warfarin for
stroke prevention still underused in atrial ﬁbrillation: patterns
of omission. Stroke 2000;31:1217—22.
[87
32] Inoue H, Nozawa T, Okumura K, et al. Attitudes of Japanese
cardiologists toward anticoagulation for nonvalvular atrial
ﬁbrillation and reasons for its underuse. Circ J 2004;68:
417—21.
33] Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the
use of anticoagulants among older adults with atrial ﬁbrilla-
tion. Arch Intern Med 1999;159:1574—8.
34] Choudhry NK, Soumerai SB, Normand SL, et al. Warfarin pre-
scribing in atrial ﬁbrillation: the impact of physician, patient,
and hospital characteristics. Am J Med 2006;119:607—15.
35] Guo GB, Chang HW, Chen MC, et al. Underutilization of anti-
coagulation therapy in chronic atrial ﬁbrillation. Jpn Heart J
2001;42:55—65.
36] Baczek VL, Chen WT, Kluger J, et al. Predictors of warfarin use
in atrial ﬁbrillation in the United States: a systematic review
and meta-analysis. BMC Fam Pract 2012;13:5.
37] Lip GY, Nieuwlaat R, Pisters R, et al. Reﬁning clinical risk
stratiﬁcation for predicting stroke and thromboembolism in
atrial ﬁbrillation using a novel risk factor-based approach:
the euro heart survey on atrial ﬁbrillation. Chest 2010;137:
263—72.
38] Lip GY, Frison L, Halperin JL, et al. Comparative validation of a
novel risk score for predicting bleeding risk in anticoagulated
patients with atrial ﬁbrillation: the HAS-BLED (Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or
Predisposition, Labile INR, Elderly Drugs/Alcohol Concomi-
tantly) score. J Am Coll Cardiol 2011;57:173—80.39] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly
score (HAS-BLED) to assess 1-year risk of major bleeding in
patients with atrial ﬁbrillation: the Euro Heart Survey. Chest
2010;138:1093—100.
